Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Daily injections of parathyroid hormone (teriparatide, or PTH 1-34) work because intermittent, short-lived spikes in PTH stimulate bone-forming osteoblasts more than bone-destroying osteoclasts, a phenomenon called the anabolic window. Continuous PTH exposure, as in hyperparathyroidism, does the opposite and breaks bone down. Each daily dose activates PTH receptors on osteoblast precursors and osteocytes, reduces sclerostin, boosts IGF-1 and Wnt signaling, and recruits new bone-forming cells that lay down fresh collagen matrix, which then mineralizes into stronger trabecular and cortical bone. Studies show meaningful gains in spine bone density and large reductions in vertebral fracture risk, with benefits typically greatest in the first 12 to 24 months before the anabolic effect plateaus. Timing, sequencing with antiresorptive drugs, treatment duration limits, monitoring for high calcium, and individual fracture risk all shape whether this therapy is right for you, and there are several important factors to consider. See below to understand more.
Bone pain, fractures, height loss, and fatigue can have many causes beyond osteoporosis, and the right next step depends on your full clinical picture. A free, instant, online symptom check can help you organize your symptoms, spot patterns worth discussing, and understand which specialists or tests may matter most, so you walk into your next appointment prepared rather than guessing.
Last reviewed for medical accuracy: 08/18/2026Daily parathyroid hormone injections (teriparatide, PTH 1-34) rebuild bone because brief, intermittent PTH spikes stimulate bone-building osteoblasts more than bone-resorbing osteoclasts, an effect known as the anabolic window, whereas continuous PTH exposure breaks bone down. Each dose activates PTH receptors on osteoblast precursors and osteocytes, lowers sclerostin, increases IGF-1 and Wnt signaling, and recruits new cells that lay down fresh collagen matrix that mineralizes into stronger trabecular and cortical bone. Clinical studies show substantial spine bone density gains and large reductions in vertebral fracture risk, with the greatest benefit generally in the first 12 to 24 months before the anabolic effect plateaus. Treatment timing, sequencing with antiresorptive drugs, duration limits, calcium monitoring, and personal fracture risk all determine whether this therapy fits your situation. There are several important factors to consider, so see below to understand more.
Bone pain, fractures, height loss, and fatigue can stem from many conditions beyond osteoporosis, and the right next step depends on your complete clinical picture rather than one symptom alone. A free, instant, online symptom check can help you organize your symptoms, spot patterns worth raising with your cl
Osteoporosis and other conditions that weaken bone can leave people vulnerable to fractures and long-term disability. One of the most exciting advances in treating fragile bones involves using a fragment of the parathyroid hormone (PTH) called teriparatide. Marketed as Forteo, teriparatide daily injections bone growth therapy represents a shift from purely anti-resorptive drugs (which slow bone loss) to an anabolic approach that actively stimulates new bone formation.
Bone is a living tissue that constantly renews itself through a balanced process called remodeling:
In healthy adults, these activities stay in equilibrium. With age, menopause, or certain diseases, bone resorption can outpace formation, resulting in low bone density and increased fracture risk.
Forteo is a synthetic form of the first 34 amino acids of human parathyroid hormone (PTH 1-34). It mimics the body’s own PTH but is dosed once daily to take advantage of a unique bone-building window:
Key phrase: Forteo teriparatide daily injections bone growth
Signal Amplification
Teriparatide binds to PTH receptors on osteoblasts, triggering a cascade that increases bone-forming proteins (e.g., collagen type I, osteocalcin).
Osteoblast Differentiation
Precursor cells in the bone marrow convert into active osteoblasts more rapidly.
Inhibition of Osteoblast Apoptosis
The therapy prolongs osteoblast lifespan, allowing them to lay down more bone matrix.
Improved Trabecular Architecture
Spongy bone (trabeculae) thickens and reconnects, bolstering resistance to compression and bending forces.
Cortical Bone Effects
Outer bone layers gain density, reducing the chance of hip and long-bone fractures.
Key phrase: Forteo teriparatide daily injections bone growth
Neer et al. (2001)
In a landmark randomized trial of postmenopausal women, teriparatide 20 µg daily reduced vertebral fractures by 65% and nonvertebral fractures by 53%, compared to placebo, over 21 months.
Men and Glucocorticoid-Induced Osteoporosis
Similar fracture risk reductions observed in men and patients on long-term steroids.
Comparison to Anti-Resorptives
Head-to-head studies with bisphosphonates (like alendronate) show greater increases in bone mineral density (BMD) with teriparatide, especially in the spine.
Key phrase: Forteo teriparatide daily injections bone growth
While teriparatide is generally well tolerated, be aware of:
Nausea or Dizziness
Often mild and transient; taking injections after meals may help.
Injection-Site Reactions
Redness or mild pain at the injection spot.
Hypercalcemia
A temporary rise in blood calcium can occur. Your doctor will monitor levels.
Orthostatic Hypotension
Rarely, a drop in blood pressure when standing up; sit or lie down if you feel lightheaded.
Theoretical Osteosarcoma Risk
In rats given very high doses for life, a small increase in bone cancer was seen. Human data haven’t shown this risk at prescribed doses, but use is limited to 2 years as a precaution.
Teriparatide is typically reserved for those at highest fracture risk, including:
Self-Injection Training
Your healthcare provider or pharmacist will show you how to mix and inject the medication safely.
Storage
Store refrigerated; allow to warm to room temperature before injecting.
Cost and Insurance
Forteo can be expensive. Many plans offer copay assistance or patient support programs.
After Teriparatide
Transition to an anti-resorptive (e.g., bisphosphonate or denosumab) is usually recommended to maintain gains in bone density.
Calcium and Vitamin D
Ensure adequate intake (1,000–1,200 mg calcium; 600–800 IU vitamin D daily).
Weight-Bearing Exercise
Walking, dancing, or resistance training strengthens bone.
Fall Prevention
Remove tripping hazards at home, use supportive footwear, and consider balance exercises.
Avoid Smoking and Excessive Alcohol
Both can impair bone formation and increase fracture risk.
If you experience any of the following, talk to your doctor promptly:
You might also consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to get guidance on whether you need immediate medical attention.
Forteo teriparatide daily injections bone growth therapy represents a powerful option for rebuilding fragile bone matrix in patients at high risk of fracture. By harnessing the anabolic effects of parathyroid hormone, teriparatide shifts the balance of bone remodeling toward formation, improving bone density and structure. As with any prescription treatment, it’s vital to discuss benefits, risks, and your personal health profile with your doctor to determine if this therapy is right for you.
Speak to a doctor about any serious or life-threatening concerns, and to develop a comprehensive plan that includes medication, nutrition, and lifestyle measures aimed at keeping your bones strong for life.
(References)
* Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, Burnett-Bowie SA, Neer RM, Leder BZ. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15. PMID: 23683600; PMCID: PMC4083737.
* Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SA. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015 Sep 19;386(9999):1147-55. doi: 10.1016/S0140-6736(15)61120-5. Epub 2015 Jul 2. PMID: 26144908; PMCID: PMC4620731.
* Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, ACTIVE Study Investigators. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial. JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136. PMID: 27533157.
* Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2. Epub 2017 Nov 9. PMID: 29129436.
* Vilaca T, Eastell R, Schini M. Osteoporosis in men. Lancet Diabetes Endocrinol. 2022 Apr;10(4):273-283. doi: 10.1016/S2213-8587(22)00012-2. Epub 2022 Mar 2. PMID: 35247315.
* Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022 Mar 12;399(10329):1080-1092. doi: 10.1016/S0140-6736(21)02646-5. PMID: 35279261.
* Amin U, McPartland A, O'Sullivan M, Silke C. An overview of the management of osteoporosis in the aging female population. Womens Health (Lond). 2023 Jan-Dec;19:17455057231176655. doi: 10.1177/17455057231176655. PMID: 37218715; PMCID: PMC10214060.
* Ebina K, Etani Y, Noguchi T, Nakata K, Okada S. Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis. J Bone Miner Metab. 2025 Jan;43(1):3-9. doi: 10.1007/s00774-024-01536-0. Epub 2024 Jul 15. PMID: 39009890; PMCID: PMC11954689.
* Veronese N, Briot K, Guañabens N, Albergaria BH, Alokail M, Al-Daghri N, Bemden AB, Bruyère O, Burlet N, Cooper C, Curtis EM, Ebeling PR, Halbout P, Hesse E, Hiligsmann M, Camargos BM, Harvey NC, Perez AD, Radermecker RP, Reginster JY, Rizzoli R, Siggelkow H, Cortet B, Brandi ML. Recommendations for the optimal use of bone forming agents in osteoporosis. Aging Clin Exp Res. 2024 Aug 9;36(1):167. doi: 10.1007/s40520-024-02826-3. Epub 2024 Aug 9. PMID: 39120740; PMCID: PMC11315730.
* Sølling AS, Langdahl BL, Cosman F. Recent Advances in Osteoporosis Therapeutics. Annu Rev Med. 2026 Jan;77(1):433-448. doi: 10.1146/annurev-med-050124-040555. Epub 2025 Nov 18. PMID: 41252575.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.